keyword
MENU ▼
Read by QxMD icon Read
search

febrile neutropenia in cancer

keyword
https://www.readbyqxmd.com/read/27918351/pediatric-oncology-discharges-with-febrile-neutropenia-variation-in-location-of-care
#1
Elysia Alvarez, Lisa J Chamberlain, Catherine Aftandilian, Olga Saynina, Paul Wise
We examined the use of Pediatric Cancer Specialty Centers (PCSCs) over time and the length of stay (LOS) in pediatric oncology patients with a diagnosis of febrile neutropenia. PCSCs were defined as Children's Oncology Group and California Children's Services designated centers. We performed a retrospective analysis on all discharges of pediatric (0 to 18) oncology patients with febrile neutropenia in California (1983 to 2011) using the private Office of Statewide Health Planning and Development database. We examined influence of age, sex, race/ethnicity, payer, income, distance, tumor type, and complications on utilization of PCSCs and LOS (SAS 9...
December 1, 2016: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/27908980/phase-2-study-of-eribulin-in-patients-with-previously-treated-advanced-or-metastatic-soft-tissue-sarcoma
#2
Akira Kawai, Nobuhito Araki, Yoichi Naito, Toshifumi Ozaki, Hideshi Sugiura, Yasuo Yazawa, Hideo Morioka, Akihiko Matsumine, Kenichi Saito, Shun Asami, Kazuo Isu
OBJECTIVE: Eribulin, a microtubule dynamics inhibitor, is approved for the treatment of patients with breast cancer and soft tissue sarcoma. We investigated the efficacy and safety of eribulin in Japanese patients with soft tissue sarcoma. METHODS: This open-label, multicenter, nonrandomized, Phase 2 study enrolled Japanese patients with measurable, advanced/metastatic soft tissue sarcoma of high/intermediate grade and ≥1 prior chemotherapy for advanced disease...
December 1, 2016: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27907921/feasibility-of-preoperative-chemotherapy-with-docetaxel-cisplatin-and-5-fluorouracil-versus-adriamycin-cisplatin-and-5-fluorouracil-for-resectable-advanced-esophageal-cancer
#3
Osamu Shiraishi, Makoto Yamasaki, Tomoki Makino, Masaaki Motoori, Hiroshi Miyata, Masayuki Shinkai, Yutaka Kimura, Motohiro Hirao, Kazumasa Fujitani, Shigeyuki Tamura, Kenji Kobayashi, Masahiko Yano, Yuichiro Doki, Takushi Yasuda
BACKGROUND: Neoadjuvant chemotherapy for resectable advanced esophageal squamous cell carcinoma (ESCC) requires reassessment. We have conducted a trial aiming at the comparison between DCF and ACF concerning perioperative adverse events. METHODS: Patients were randomly assigned to receive either DCF [docetaxel 70 mg/m2, cisplatin 70 mg/m2 on day 1, and 5-fluorouracil (5-FU) 700 mg/m2 for 5 days] every 3 weeks or ACF (adriamycin 35 mg/m2, cisplatin 70 mg/m2 on day 1, and 5-FU 700 mg/m2 for 7 days) every 4 weeks...
December 2, 2016: Oncology
https://www.readbyqxmd.com/read/27904453/outcome-of-severe-infections-in-afebrile-neutropenic-cancer-patients
#4
Ksenija Strojnik, Ksenija Mahkovic-Hergouth, Barbara Jezersek Novakovic, Bostjan Seruga
BACKGROUND: In some neutropenic cancer patients fever may be absent despite microbiologically and/or clinically confirmed infection. We hypothesized that afebrile neutropenic cancer patients with severe infections have worse outcome as compared to cancer patients with febrile neutropenia. PATIENTS AND METHODS: We retrospectively analyzed all adult cancer patients with chemotherapy-induced neutropenia and severe infection, who were admitted to the Intensive Care Unit at our cancer center between 2000 and 2011...
December 1, 2016: Radiology and Oncology
https://www.readbyqxmd.com/read/27903924/randomized-phase-ii-study-of-cabazitaxel-versus-methotrexate-in-patients-with-recurrent-and-or-metastatic-squamous-cell-carcinoma-of-the-head-and-neck-previously-treated-with-platinum-based-therapy
#5
Jean-Pascal Henry Machiels, Aline Van Maanen, Jean-Marie Vandenbulcke, Bertrand Filleul, Emmanuel Seront, Stéphanie Henry, Lionel D'Hondt, Christophe Lonchay, Stéphane Holbrechts, Petra Boegner, Dany Brohee, Didier Dequanter, Ingrid Louviaux, Brieuc Sautois, Nicolas Whenham, Guy Berchem, Brigitte Vanderschueren, Christel Fontaine, Sandra Schmitz, Aline Gillain, Joelle Schoonjans, Sylvie Rottey
LESSONS LEARNED: Cabazitaxel has activity in squamous cell carcinoma of the head and neck (SCCHN) and taxane-resistant cell lines. For the first time, cabazitaxel was investigated in incurable patients with recurrent SCCHN. Patients were randomly assigned to cabazitaxel every 3 weeks or weekly methotrexate.This phase II study did not meet its primary endpoint.Cabazitaxel has low activity in SCCHN.The toxicity profile in this population also was not favorable owing to the high rate of febrile neutropenia observed (17%)...
November 30, 2016: Oncologist
https://www.readbyqxmd.com/read/27899784/-effectiveness-of-carboplatin-plus-taxane-chemotherapy-for-advanced-or-recurrent-uterine-serous-carcinoma
#6
Takuto Matsuura, Isao Otsuka
OBJECTIVE: Uterine serous carcinoma(USC)is more aggressive compared to endometrioid adenocarcinoma, and often exhibits intraperitoneal spread, resulting in a poor prognosis. It is a rare subtype of uterine cancers, accounting for 5%of cases in Japan; therefore, optimal chemotherapy regimens for patients with advanced or recurrent disease have not been established. In the present study, we evaluated the safety and efficacy of carboplatin plus taxane chemotherapy for the treatment of patients withadvanced and recurrent USC...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/27876404/very-early-discharge-compared-with-early-or-non-early-discharge-in-children-with-cancer-and-febrile-neutropenia-a-cochrane-review-summary
#7
Natalie Bradford
No abstract text is available yet for this article.
July 6, 2016: International Journal of Nursing Studies
https://www.readbyqxmd.com/read/27868411/-efficacy-of-neoadjuvant-chemotherapy-combined-with-bevacizumab-versus-neoadjuvant-chemotherapy-alone-for-her2-negative-breast-cancer-a-meta-analysis-of-randomized-controlled-clinical-trials
#8
Rui Han, Guanying Wang, Yujiao Zhang, Xinhan Zhao
Objective: To evaluate the efficacy and safety of neoadjuvant chemotherapy combined with bevacizumab versus neoadjuvant chemotherapy alone for Her2-negative breast cancer.Methods: We searched PubMed, the Cochrane Library, Web of Science, CNKI, Wanfang Database and the abstracts of major international conferences in recent 5 years to identify prospective randomized controlled clinical trials that met the inclusion and exclusion criteria. Study selection and analyses were undertaken according to the Cochrane Handbook...
May 25, 2016: Zhejiang da Xue Xue Bao. Yi Xue Ban, Journal of Zhejiang University. Medical Sciences
https://www.readbyqxmd.com/read/27868231/aprepitant-in-pediatric-patients-using-moderate-and-highly-emetogenic-protocols-a-systematic-review-and-meta-analyses-of-randomized-controlled-trials
#9
Lucas Miyake Okumura, Fernanda D' Athayde Rodrigues, Maria Angelica Pires Ferreira, Leila Beltrami Moreira
AIMS: To review the efficacy and safety of aprepitant in combination with ondansetron and dexamethasone (triple therapy) in children and adolescents on moderate to highly emetogenic chemotherapy. METHODS: Medline, Embase, Scielo, Lilacs, Cochrane and congress abstracts published until September 2016 were used as data sources. Two reviewers independently selected manuscripts and extracted data. A third reviewer solved discrepancies in study's selection and data extraction...
November 20, 2016: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27865372/phase-ii-study-of-panitumumab-and-paclitaxel-as-first-line-treatment-in-recurrent-or-metastatic-head-and-neck-cancer-ttcc-2009-03-vectitax-study
#10
Elvira Del Barco Morillo, Ricard Mesía, Juan Carlos Adansa Klain, Silvia Vázquez Fernández, Joaquina Martínez-Galán, Miguel Pastor Borgoñon, Cyntia González-Rivas, Javier Caballero Daroqui, Alfonso Berrocal, Javier Martínez-Trufero, Ruth Vera, Juan Jesús Cruz-Hernández
OBJECTIVE: To evaluate the activity and safety profile of panitumumab in combination with paclitaxel in patients with recurrent or metastatic SCCHN. MATERIALS AND METHODS: The VECTITAX phase II, open-label, multicenter study included patients with confirmed metastatic and/or recurrent SCCHN deemed to be untreatable by surgery or radiotherapy and ECOG PS=0-1. All patients received paclitaxel (80mg/m(2)/week) and panitumumab (6mg/kg/2weeks) until disease progression or unacceptable toxicity...
November 2016: Oral Oncology
https://www.readbyqxmd.com/read/27863724/-which-approach-of-therapeutic-education-te-for-adolescents-and-young-adults-with-cancer-experience-from-the-te-working-group-of-go-aja
#11
Nadège Corradini, Loïc Dagorne, Marielle Retailleau, Françoise Rédini, Hélène Sudour-Bonnange, Leila Gofti-Laroche, Anne Le Rhun, Nathalie Gaspar
INTRODUCTION: Therapeutic education (TE) is a practice developed over 40 years at an international level to give people with chronic illness the skills necessary to help them better manage their disease. The lengthening survival time of cancer patients as well as changes in the patient-caregiver relationship have contributed to the development of TE in oncologic diseases. Every year in France, about 1900 adolescents and young adults (15-25 years old) are diagnosed with cancer which is the second leading cause of death in this age group...
November 15, 2016: Bulletin du Cancer
https://www.readbyqxmd.com/read/27862097/phase-ib-trial-of-cabazitaxel-and-tasquinimod-in-men-with-heavily-pretreated-metastatic-castration-resistant-prostate-cancer-mcrpc-the-catch-trial
#12
Andrew J Armstrong, Michael S Humeniuk, Patrick Healy, Russell Szmulewitz, Carolyn Winters, Julie Kephart, Michael R Harrison, Elia Martinez, Kelly Mundy, Susan Halabi, Daniel George
BACKGROUND: Tasquinimod is an immunomodulating and anti-antiangiogenic oral agent with anti-prostate cancer activity in preclinical studies and in clinical trials of men with metastatic castration resistant prostate cancer (mCRPC), including single agent activity and in combination with taxanes. We sought to identify the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of tasquinimod in combination with cabazitaxel and prednisone in men with chemorefractory mCRPC. METHODS: Men with mCRPC who had failed prior docetaxel chemotherapy received cabazitaxel 25 mg/m(2) every 3 weeks with oral tasquinimod at 1 of 3 escalating dose levels (0...
November 16, 2016: Prostate
https://www.readbyqxmd.com/read/27860223/validation-of-risk-stratification-for-children-with-febrile-neutropenia-in-a-pediatric-oncology-unit-in-india
#13
Anirban Das, Amita Trehan, Sapna Oberoi, Deepak Bansal
PURPOSE: The study aims to validate a score predicting risk of complications in pediatric patients with chemotherapy-related febrile neutropenia (FN) and evaluate the performance of previously published models for risk stratification. PATIENTS AND METHODS: Children diagnosed with cancer and presenting with FN were evaluated in a prospective single-center study. A score predicting the risk of complications, previously derived in the unit, was validated on a prospective cohort...
November 15, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27858180/irinotecan-monotherapy-as-third-line-treatment-for-advanced-gastric-cancer-refractory-to-fluoropyrimidines-platinum-and-taxanes
#14
Takashi Nishimura, Satoru Iwasa, Kengo Nagashima, Natsuko Okita, Atsuo Takashima, Yoshitaka Honma, Ken Kato, Tetsuya Hamaguchi, Yasuhide Yamada, Yasuhiro Shimada, Narikazu Boku
BACKGROUND: Because standard chemotherapy for advanced gastric cancer consists of oral fluoropyrimidines plus platinum as first-line therapy, with paclitaxel plus ramucirumab as the second line, irinotecan is usually positioned as third-line chemotherapy in clinical practice in Japan. METHODS: A retrospective evaluation was conducted to determine the efficacy and safety of irinotecan as third-line chemotherapy for advanced gastric cancer in patients refractory or intolerant to fluoropyrimidines, platinum, and taxanes...
November 17, 2016: Gastric Cancer
https://www.readbyqxmd.com/read/27831502/dual-her2-blockade-with-pertuzumab-and-trastuzumab-in-her2-positive-early-breast-cancer-a-subanalysis-of-data-from-the-randomized-phase-iii-geparsepto-trial
#15
S Loibl, C Jackisch, A Schneeweiss, S Schmatloch, B Aktas, C Denkert, H Wiebringhaus, S Kümmel, M Warm, S Paepke, M Just, C Hanusch, J Hackmann, J-U Blohmer, M Clemens, S Dan Costa, B Gerber, K Engels, V Nekljudova, G von Minckwitz, M Untch
BACKGROUND: The neoadjuvant phase III GeparSepto study showed that substituting nab-paclitaxel for standard solvent-based paclitaxel significantly improved the pathologic complete response (pCR) rate achieved with a sequential neoadjuvant chemotherapy regimen of paclitaxel, epirubicin and cyclophosphamide for high-risk primary breast cancer. Recent trials demonstrated that in HER2+ breast cancer pCR can be increased by using pertuzumab in addition to trastuzumab and chemotherapy. The present analysis focuses on efficacy and safety data from the subset of patients with HER2+ tumors from the GeparSepto trial (n=396) in comparison to the HER2- cohort...
November 9, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27830043/phase-ii-study-of-docetaxel-cisplatin-and-capecitabine-as-preoperative-chemotherapy-in-resectable-gastric-cancer
#16
Anneriet E Dassen, Nienke Bernards, Valery E P P Lemmens, Yes A J van de Wouw, Koop Bosscha, Geert-Jan Creemers, Hans J F M Pruijt
AIM: To investigate the feasibility of preoperative docetaxel, cisplatin and capecitabine (DCC) in patients with resectable gastric cancer. METHODS: Patients with resectable gastric cancer fulfilling the inclusion criteria, were treated with 4 cycles of docetaxel (60 mg/m(2)), cisplatin (60 mg/m(2)) and capecitabine (1.875 mg/m(2) orally on day 1-14, two daily doses) repeated every three weeks, followed by surgery. Primary end point was the feasibility and toxicity/safety profile of DCC, secondary endpoints were pathological complete resection rate and pathological complete response (pCR) rate...
October 27, 2016: World Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/27829539/chemotherapy-induced-febrile-neutropenia-prophylaxis-with-biosimilar-filgrastim-in-elderly-versus-non-elderly-cancer-patients-patterns-outcomes-and-determinants-monitor-gcsf-study
#17
Matti Aapro, Carsten Bokemeyer, Heinz Ludwig, Pere Gascón, Mario Boccadoro, Kris Denhaerynck, Michael Gorray, Andriy Krendyukov, Karen MacDonald, Ivo Abraham
BACKGROUND: Myelotoxic chemotherapy is associated with chemotherapy-induced (febrile) neutropenia (CIN/FN). The MONITOR-GCSF study evaluated biosimilar filgrastim (Zarzio®) prophylaxis patterns, associated outcomes, and determinants. We performed stratified analyses comparing elderly and non-elderly patients. METHODS: Comparative (elderly/non-elderly) analysis of demographics and clinical status, prophylaxis, associated CIN/FN outcomes (CIN grade 4 [CIN4], FN, CIN/FN-related hospitalizations and chemodisturbances, composite), and, per hierarchical modeling, determinants thereof evaluated at the patient- and cycle-level...
November 6, 2016: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/27817239/modified-docetaxel-cisplatin-and-fluorouracil-therapy-as-the-first-line-treatment-for-patients-with-recurrent-metastatic-squamous-cell-carcinoma-of-the-head-and-neck-cancer-a-retrospective-study
#18
Nebi Serkan Demirci, Sercan Aksoy, Nuriye Yıldırım Özdemir, Gökmen Umut Erdem, Melike Ozcelik, Eda Tanrikulu, Tülay Eren, Yakup Bozkaya, Süleyman Sahin, Fatma Başol, Suheyla Aytac Aslan, Nurullah Zengin, İbrahim Güllü
AIM: Modified DCF (mDCF) therapy has been shown to be well-tolerated and highly effective regimen for metastatic gastric carcinoma. Herein we investigated the effectiveness of mDCF combination as the first-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer (HNSCC). METHODS: A total of 80 patients with recurrent/metastatic HNSCC who were treated with mDCF between 2009 and 2015 were enrolled into this study. All patients were treated as the first-line with 2-6 cycles of mDCF chemotherapy which consisted of docetaxel 60 mg/m(2) intravenously (IV) on day 1, cisplatin 60 mg/m(2) IV on day 1, and 5-fluorouracil 600 mg/m(2) IV for 5 days of continuous infusion, with cycles repeated every 21 days...
November 5, 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/27817104/prevention-of-granulocyte-colony-stimulating-factor-g-csf-induced-bone-pain-using-double-histamine-blockade
#19
Elizabeth Gavioli, Misty Abrams
PURPOSE: Febrile neutropenia (FN) is an oncological emergency that may reduce patient survival due to chemotherapy dose delays or reductions. It is recommended that patients at risk for FN receive prophylaxis with granulocyte-colony stimulating factor (G-CSF). Bone pain is a common side effect through a mechanism not fully understood. It is thought to be due to histamine release from an inflammatory response. METHODS: This was a retrospective cohort from January to November 2015...
November 5, 2016: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/27811367/a-network-meta-analysis-for-toxicity-of-eight-chemotherapy-regimens-in-the-treatment-of-metastatic-advanced-breast-cancer
#20
Xiao-Hua Zhang, Shuai Hao, Bo Gao, Wu-Guo Tian, Yan Jiang, Shu Zhang, Ling-Ji Guo, Dong-Lin Luo
OBJECTIVE: To compare the incidence of toxicity of 8 different chemotherapy regimens, including doxorubicin + paclitaxel, doxorubicin, capecitabine, CMF (cyclophosphamide + methotrexate + 5-fluorouracil), FAC (fluorouracil + doxorubicin + cyclophosphamide), doxorubicin + docetaxel, doxorubicin + cyclophosphamide and paclitaxel in the treatment of metastatic/advanced breast cancer. RESULTS: This network meta-analysis included 8 randomized controlled trials (RCTs)...
November 2, 2016: Oncotarget
keyword
keyword
95633
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"